 First Wave BioPharma Inc NASDAQ: FWBI shares are plummeting after the company reported topline data from Phase 2 RESERVOIR trial of FW-COV, oral formulation of niclosamide, for COVID-19-related GI infections. FW-COV was very safe, with no serious adverse events reported by the more than 150. 